Ubs Asset Management Americas Inc Kymera Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 896,404 shares of KYMR stock, worth $39.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
896,404
Previous 404,667
121.52%
Holding current value
$39.5 Million
Previous $16.3 Million
50.71%
% of portfolio
0.01%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding KYMR
# of Institutions
181Shares Held
67.4MCall Options Held
223KPut Options Held
241K-
Price T Rowe Associates Inc Baltimore, MD6.7MShares$296 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.46MShares$285 Million2.86% of portfolio
-
Wellington Management Group LLP Boston, MA6MShares$265 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$265 Million1.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.23MShares$231 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.41B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...